Publications 2022

Rimstad R, Løkkevik E, Juul-Hansen KE, Holtan A (2022)
Patient needs in evacuation of a tertiary oncology center
J Emerg Manag, 20 (3), 267-272
DOI 10.5055/jem.0626, PubMed 35792815

Publications 2015

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE (2015)
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
Mol Oncol, 9 (8), 1553-64
DOI 10.1016/j.molonc.2015.04.008, PubMed 26004085

Publications 2012

Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V (2012)
Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
ISRN Oncol, 2012, 176789
DOI 10.5402/2012/176789, PubMed 22666610

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE (2012)
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
Breast Cancer Res, 14 (2), R47
DOI 10.1186/bcr3147, PubMed 22420423

Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E, Norwegian Breast Cancer Group trial NBCG VI, Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE (2012)
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
PLoS One, 7 (4), e36263
DOI 10.1371/journal.pone.0036263, PubMed 22558411

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B (2012)
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
Breast Cancer Res, 14 (4), R117
DOI 10.1186/bcr3242, PubMed 22889108

Wist EA, Mjaaland I, Løkkevik E, Sommer HH (2012)
Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
J Oncol, 2012, 862921
DOI 10.1155/2012/862921, PubMed 22291703

Publications 2011

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE (2011)
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel
PLoS One, 6 (4), e19249
DOI 10.1371/journal.pone.0019249, PubMed 21556366

Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS et al. (2011)
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
Cancer Cell, 19 (2), 273-82
DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605

Publications 2008

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE (2008)
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer
PLoS One, 3 (8), e3062
DOI 10.1371/journal.pone.0003062, PubMed 18725978

Nesvold IL, Dahl AA, Løkkevik E, Marit Mengshoel A, Fosså SD (2008)
Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy
Acta Oncol, 47 (5), 835-42
DOI 10.1080/02841860801961257, PubMed 18568481

Vågane R, Danielsen T, Fosså SD, Løkkevik E, Olsen DR (2008)
Late regional density changes of the lung after radiotherapy for breast cancer
Radiother Oncol, 90 (1), 148-52
DOI 10.1016/j.radonc.2007.12.031, PubMed 18262670

Publications 2006

Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J (2006)
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study
Eur J Cancer, 42 (17), 2968-75
DOI 10.1016/j.ejca.2006.07.005, PubMed 16963261

Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE (2006)
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer
Clin Cancer Res, 12 (20 Pt 1), 6000-4
DOI 10.1158/1078-0432.CCR-05-2822, PubMed 17062672

Publications 2001

Berentsen S, Tjønnfjord GE, Brudevold R, Gjertsen BT, Langholm R, Løkkevik E, Sørbø JH, Ulvestad E (2001)
Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease
Br J Haematol, 115 (1), 79-83
DOI 10.1046/j.1365-2141.2001.03078.x, PubMed 11722415

Evensen JF, Bjordal K, Jacobsen AB, Løkkevik E, Tausjø JE (2001)
Effects of Na-sucrose octasulfate on skin and mucosa reactions during radiotherapy of head and neck cancers--a randomized prospective study
Acta Oncol, 40 (6), 751-5
DOI 10.1080/02841860152619188, PubMed 11765071

Publications 1996

Løkkevik E (1996)
[Treatment with growth factors and cytokines in hematological diseases]
Tidsskr Nor Laegeforen, 116 (19), 2352-3
PubMed 8804216

Løkkevik E, Skovlund E, Reitan JB, Hannisdal E, Tanum G (1996)
Skin treatment with bepanthen cream versus no cream during radiotherapy--a randomized controlled trial
Acta Oncol, 35 (8), 1021-6
DOI 10.3109/02841869609100721, PubMed 9023388